Mr. Peter Halling is President & CEO of ALK-Abelló A/S from 2023. Mr. Peter Halling serves as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experience from working in...

리더십 팀

이름	위치	테뉴어	보상	소유권
Claus Solje	Executive VP	less than a year	kr.14.86m	데이터 없음
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12.1yrs	kr.6.51m	0.020% DKK 6.3m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.3yrs	kr.7.18m	데이터 없음
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	kr.350.00k	데이터 없음
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	kr.270.00k	데이터 없음
Peter Halling	President & CEO	1.4yrs	데이터 없음	데이터 없음
Per Plotnikof	VP of Corporate Communications	no data	데이터 없음	데이터 없음
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.3yrs	데이터 없음	데이터 없음
Christian Houghton	Head of Product Supply	5.4yrs	데이터 없음	데이터 없음
Peter Andersen	Senior Vice President of Global Research & Drug Discovery	no data	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: ALK B 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.4yrs	kr.350.00k	데이터 없음
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.3yrs	kr.270.00k	데이터 없음
Jesper Hoiland	Independent Director	1.3yrs	kr.366.00k	데이터 없음
Lene Skole-Sorensen	Vice Chairman of the Board	10.4yrs	kr.900.00k	데이터 없음
Anders Hedegaard	Independent Chairman of the Board	4.3yrs	kr.1.33m	데이터 없음
Lars Holmqvist	Director	9.3yrs	kr.446.00k	데이터 없음
Gitte Aabo	Independent Director	3.3yrs	kr.523.00k	데이터 없음
Alan Main	Independent Director	2.3yrs	kr.450.00k	데이터 없음
Bertil Lindmark	Independent Director	3.3yrs	kr.500.00k	데이터 없음
Nanna Carlson	Employee Representative Director	5.3yrs	kr.350.00k	데이터 없음
Johan Smedsrud	Employee Representative Director	5.3yrs	kr.350.00k	데이터 없음

4.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: ALK B 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

ALK-Abelló 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insider recently sold kr.9.0m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Now 20% undervalued

Investor sentiment improves as stock rises 17%

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Insider recently sold kr.9.0m worth of stock

Price target increased by 7.8% to kr.121

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Price target decreased by 7.3% to kr.109

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Price target decreased by 9.2% to kr.116

Investor sentiment deteriorates as stock falls 15%

New major risk - Share price stability

Alk-Abelló A/S Announces Executive Changes

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Price target decreased by 8.5% to kr.129

Investor sentiment deteriorates as stock falls 22%

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

ALK Announces Management Changes

Full year 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Price target decreased to kr.161

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Now 20% undervalued after recent price drop

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 21% undervalued

Alk-Abelló A/S Announces Executive Changes

First quarter 2022 earnings: Revenues exceed analyst expectations

Now 20% undervalued

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022